Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.

Autor: Pettus J; Division of Endocrinology, University of California San Diego, La Jolla, CA, USA. jpettus@health.ucsd.edu., Boeder SC; Division of Endocrinology, University of California San Diego, La Jolla, CA, USA., Christiansen MP; Diablo Clinical Research, Walnut Creek, CA, USA., Denham DS; Clinical Trials of Texas, San Antonio, TX, USA., Bailey TS; AMCR Institute, Escondido, CA, USA., Akturk HK; Barbara Davis Center for Diabetes, University of Colorado Anschutz Campus, Aurora, CO, USA., Klaff LJ; Rainier Clinical Research Center, Renton, WA, USA., Rosenstock J; Dallas Diabetes Research Center, Dallas, TX, USA., Cheng MHM; Marin Endocrine Care and Research, Greenbrae, CA, USA., Bode BW; Atlanta Diabetes Associates, Atlanta, GA, USA., Bautista ED; REMD Biotherapeutics, Camarillo, CA, USA., Xu R; REMD Biotherapeutics, Camarillo, CA, USA., Yan H; REMD Biotherapeutics, Camarillo, CA, USA., Thai D; REMD Biotherapeutics, Camarillo, CA, USA., Garg SK; Barbara Davis Center for Diabetes, University of Colorado Anschutz Campus, Aurora, CO, USA., Klein S; Center for Human Nutrition, Washington University School of Medicine, St. Louis, MO and Sansum Diabetes Research Institute, Santa Barbara, CA, USA.
Jazyk: angličtina
Zdroj: Nature medicine [Nat Med] 2023 Nov; Vol. 29 (11), pp. 2959.
DOI: 10.1038/s41591-023-02301-y
Databáze: MEDLINE